AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

AGN:CSE AGNPF:OTCQB AGW:FSE

View Company News

Visit Company Website

Expert Comments:

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
(3/30/21)

Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure.

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates
(3/22/21)

Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about.

Pharma Developer to Release Topline Data from Phase 2b COVID-19 Trial by Month-End
(3/16/21)

Algernon Pharmaceuticals reported expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021.

Biopharma Chooses Firm to Co-Conduct Psychedelic Dose Trial
(3/2/21)

Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer.

André Uddin, Research Capital Corporation

(3/1/21)

"The database of the Phase 2b part of Algernon Pharmaceuticals Inc.'s Phase 2b/3 trial with ifenprodil in COVID-19 is to be locked for analysis on March 5, 2021; final results are expected to be disclosed shortly thereafter. Results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis/chronic cough are expected in Q2/21 or Q3/21 for early chronic cough data and Q4/21 for full study data."

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial
(2/12/21)

Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol.

Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT
(2/10/21)

Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients.

Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke
(2/5/21)

This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report.

André Uddin, Research Capital Corporation

(2/2/21)

"Algernon Pharmaceuticals Inc. has established a program to repurpose a psychedelic compound, DMT, for stroke. . .the company is to continue a number of preclinical studies with DMT for stroke and is looking to file an investigational new drug application with the U.S. Food and Drug Administration based on DMT's historical data of Phase 1 clinical trials and new preclinical data generated by Algernon."

Clive Maund, CliveMaund.com

(2/1/21)

"Algernon Pharmaceuticals Inc. is looking like a Buy again here as it is at the bottom of the shallow uptrend that has developed from the December low, and a stop may be placed beneath the lower rail of the channel. An additional reason for buying the company here that may lead to a bigger move is the good news out of it this morning that it is commencing clinical research with a psychedelic drug for stroke treatment."

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study
(1/20/21)

Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2.

Pharma Developer Outlines 2021 Clinical Program Initiatives
(1/8/21)

Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials.

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease
(1/4/21)

Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.

Clive Maund, CliveMaund.com

(12/28/20)

"The good news with Algernon Pharmaceuticals Inc. is that the stock has now arrived at a much stronger long-term support level in a deeply oversold state, so the least we can expect is a significant bounce from here. On Thursday there was a moderately bullish candle on strong volume with it closing well off the lows, which suggests that it may be reversing here or at least have hit bottom."

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study
(12/21/20)

Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial.

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends'
(12/16/20)

Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report.

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial
(12/16/20)

Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators.

André Uddin, Research Capital Corporation

(12/15/20)

"Algernon Pharmaceuticals Inc. reports interim results of a COVID-19 Phase 2b/3 trial with Ifenprodil. . .The results showed two positive early trends in high-dose ifenprodil at Day 15: (i) fewer patients required mechanical ventilation and (ii) the reduction of the NEWS score (used to monitor patient status) was quicker, which could potentially translate to a faster recovery down the road. . .We are maintaining our SPECULATIVE BUY rating and TP of $0.80/share. AGN remains a high risk high reward investment opportunity."

Clive Maund, CliveMaund.com

(12/8/20)

"Algernon Pharmaceuticals Inc. is now in a vigorous uptrend. It has paused for a rest in recent days with a small bull Pennant believed to be forming. Current light volume and strong Accumulation line suggest that another upleg is imminent."

Pharma Developer Raises Enrollment Goal for Multinational Phase 2b/3 COVID-19 Trial

(11/25/20)

Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition.

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December

(11/11/20)

Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020.

Multinational Phase 2b/3 COVID-19 Study Approved to Continue

(11/2/20)

Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy.

More Expert Comments

Experts Following This Company

Knox Henderson
Dr. KSS, Founder and Editor-in-Chief – BioPub.co
Clive Maund – CliveMaund.com
	André Uddin – Research Capital Corporation

Company News

4/8/2021 – Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

4/6/2021 – Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

3/31/2021 – Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

3/29/2021 – Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

3/17/2021 – Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

3/11/2021 – Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil

3/5/2021 – Algernon Pharmaceuticals Announces Increase and Close of Private Placement

3/3/2021 – Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

3/1/2021 – Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

3/1/2021 – Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

2/19/2021 – Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

2/17/2021 – Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

2/10/2021 – Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

2/8/2021 – Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

2/3/2021 – Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

2/1/2021 – Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"

1/22/2021 – Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights

	Advancing new drug treatments for billion dollar global disease markets.
	Conducting multiple phase II clinical trials
	Experienced management team & globally recognized medical advisory board

catalyst Calendar

Q2 2021	U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4 2021	Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4 2021	Phase 1 Study planned for DMT, Q4 2021

Algernon Pharmaceuticals Inc. Content

Fact Sheet March 2021

Fact Sheet April 2020

Algernon Pharmaceuticals Inc.

Expert Comments:

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
(3/30/21)

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates
(3/22/21)

Pharma Developer to Release Topline Data from Phase 2b COVID-19 Trial by Month-End
(3/16/21)

Biopharma Chooses Firm to Co-Conduct Psychedelic Dose Trial
(3/2/21)

André Uddin, Research Capital Corporation

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial
(2/12/21)

Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT
(2/10/21)

Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke
(2/5/21)

André Uddin, Research Capital Corporation

Clive Maund, CliveMaund.com

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study
(1/20/21)

Pharma Developer Outlines 2021 Clinical Program Initiatives
(1/8/21)

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease
(1/4/21)

Clive Maund, CliveMaund.com

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study
(12/21/20)

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends'
(12/16/20)

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial
(12/16/20)

André Uddin, Research Capital Corporation

Clive Maund, CliveMaund.com

Pharma Developer Raises Enrollment Goal for Multinational Phase 2b/3 COVID-19 Trial

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December

Multinational Phase 2b/3 COVID-19 Study Approved to Continue

More Expert Comments

All Penny Stocks

André Uddin, Research Capital Corporation

Baystreet

Experts Following This Company

Company News

All Penny Stocks (8/24/20) "What a spectacular run junior biotech Algernon Pharmaceuticals Inc. has made since late-November. The stock run-up is largely predicated on one virus, COVID-19. With a brief pullback over the last few months, we think it is time to revisit this stock as the technical stars may be aligning for one more major push higher."

	André Uddin, Research Capital Corporation (8/19/20) "We are initiating coverage of Algernon Pharmaceuticals Inc. with a Speculative Buy recommendation and a target price of $0.80/share. . .Algernon is focused on developing repurposed small molecules for new disease indications – these drug candidates have been already approved in ROW markets (but not approved in the U.S. or Europe). . .Algernon's lead product, ifenprodil (a marketed drug in Japan for circulatory disorders) is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."

Baystreet (8/12/20) "Algernon Pharmaceuticals Inc. is betting that this quiet and unassuming safe generic drug, Ifenprodil, may soon become a global blockbuster. . .the company recently announced the first patient has been enrolled in its multinational human Phase 2b/3 COVID trial of Ifenprodil. . .Phase 2b data are expected before 2020E."